These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10378328)

  • 1. [Monitoring blood coagulation].
    Pabinger-Fasching I
    Wien Med Wochenschr; 1999; 149(2-4):70-1. PubMed ID: 10378328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring the new antithrombotic drugs.
    Walenga JM; Hoppensteadt DA
    Semin Thromb Hemost; 2004 Dec; 30(6):683-95. PubMed ID: 15630675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin in patients with venous thromboembolism and contraindications to oral anticoagulant therapy.
    Monreal M
    Semin Thromb Hemost; 1997; 23(1):69-75. PubMed ID: 9156413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monitoring of heparin in the treatment of deep venous thrombosis. An obsolete question?].
    Toulemonde F; Kher A
    Ann Cardiol Angeiol (Paris); 1995 Mar; 44(3):151-9. PubMed ID: 7793854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial treatment of venous thromboembolism.
    Becattini C; Agnelli G; Emmerich J; Bura A; Weitz JI
    Thromb Haemost; 2006 Sep; 96(3):242-50. PubMed ID: 16953263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of deep venous thrombosis].
    Mesters RM
    Internist (Berl); 1999 Oct; 40(10):1098-9. PubMed ID: 10610366
    [No Abstract]   [Full Text] [Related]  

  • 10. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of deep venous thromboses with heparin. Therapeutic management and biological monitoring].
    Conard J; Horellou MH; Samama M
    Ann Med Interne (Paris); 1986; 137(6):493-6. PubMed ID: 3813285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging and heparin-related bleeding.
    Campbell NR; Hull RD; Brant R; Hogan DB; Pineo GF; Raskob GE
    Arch Intern Med; 1996 Apr; 156(8):857-60. PubMed ID: 8774204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfractionated versus low-molecular-weight heparin for deep venous thrombosis.
    Penner J
    N Engl J Med; 1996 Aug; 335(9):671; author reply 671-2. PubMed ID: 8692247
    [No Abstract]   [Full Text] [Related]  

  • 15. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding and thrombosis in high-risk renal transplantation candidates using heparin.
    Mathis AS; Davé N; Shah NK; Friedman GS
    Ann Pharmacother; 2004 Apr; 38(4):537-43. PubMed ID: 14766999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of oral anticoagulant treatment in patients with venous thromboembolism.
    Pengo V
    Semin Thromb Hemost; 2006 Nov; 32(8):781-6. PubMed ID: 17171590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unfractionated versus low-molecular-weight heparin for deep venous thrombosis.
    Strandness DE
    N Engl J Med; 1996 Aug; 335(9):670-1; author reply 671-2. PubMed ID: 8692246
    [No Abstract]   [Full Text] [Related]  

  • 19. [Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
    MMW Fortschr Med; 2003 Jun; 145(24):56. PubMed ID: 12866309
    [No Abstract]   [Full Text] [Related]  

  • 20. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
    Greaves M;
    Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.